Phase 3 Readout

RZLT: Phase 3 Topline: A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Co

Name: Phase 3 Topline: A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Co
Start: 2027-09-01
End: 2027-09-01

September 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: September 1, 2027
Company: Rezolute, Inc. (RZLT)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Co

September 1, 2027

RZLT overview →

Company: Rezolute, Inc. (RZLT)
Indication: Tumor Hyperinsulinism (Tumor HI)